-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, researchers examined the effectiveness and safety of single-dose radiotherapy in tumor excision in breast cancer patients.
the study was conducted at 32 centres in 10 countries, including the UK, Europe, Australia, the United States and Canada, involving 2,298 female breast cancer patients aged 45 and over who had leachate catheter cancer of less than 3.5 cm, CN0-N1, which met the conditions for breast-feeding treatment and was randomly divided into target intraoperative radiotherapy groups (TARGIT-IORT) or postoperative introphy radiotherapy groups (EBRT).
the EBRT group received 3-6 weeks of full mammary radiation therapy, the TARGIT-ORT group received radiotherapy immediately after the lump removal, and 80% of patients received only this radiotherapy.
end of the study was 5 years local recurrence rate and long-term survival rate, and the non-inferiority boundary was 2.5%.
TARGIT-IORT group included 1,140 patients and the EBRT group contained 1,158 patients.
study concluded that TARGIT-IORT was no less effective than EBRT: at 5 years of follow-up, the local recurrence rate of TARGIT-IORT group was 2.11%, while EBRT was 0.95% (difference was 1.16%).
, TARGIT-IORT reported 13 additional local relapses (24/1140 vs. 11/1158) compared to EBRT, but 14 fewer deaths (42/1140 vs. 56/1158).
follow-up (median 8.6 years, maximum 18.90 years) showed that the local recurrence rate between groups (risk ratio 1.13), the survival rate of breast-saving surgery (0.96), no far-end There was no significant difference between the transfer survival rate (0.88), the overall survival rate (0.82) and the breast cancer mortality rate (1.12), but the mortality rate for other causes in the TARGIT-IORT group decreased significantly (0.59).
for early breast cancer patients who could receive breast care, the treatment effect of single radiotherapy was comparable to that of in-body radiation therapy after surgery, and the mortality rate from non-breast cancer was low.
.
